341 related articles for article (PubMed ID: 34983073)
21. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
[TBL] [Abstract][Full Text] [Related]
22. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
23. Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism.
Yoon D; Jeong HE; Park S; You SC; Bang SM; Shin JY
BMC Med; 2023 Sep; 21(1):375. PubMed ID: 37775786
[TBL] [Abstract][Full Text] [Related]
24. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
Kline JA; Jimenez D; Courtney DM; Ianus J; Cao L; Lensing AW; Prins MH; Wells PS
Acad Emerg Med; 2016 Feb; 23(2):144-50. PubMed ID: 26765080
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
[TBL] [Abstract][Full Text] [Related]
27. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
Sobieraj DM; Coleman CI; Pasupuleti V; Deshpande A; Kaw R; Hernandez AV
Thromb Res; 2015 May; 135(5):888-96. PubMed ID: 25795564
[TBL] [Abstract][Full Text] [Related]
29. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
Hirschl M; Kundi M
Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
[TBL] [Abstract][Full Text] [Related]
30. A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry.
Kepka S; Cordeanu EM; Zarca K; Frantz AS; Ohlmann P; Andres E; Bilbault P; Durand-Zaleski I; Stephan D
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676804
[No Abstract] [Full Text] [Related]
31. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
[TBL] [Abstract][Full Text] [Related]
32. Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
Sindet-Pedersen C; Langtved Pallisgaard J; Staerk L; Gerds TA; Fosbøl EL; Torp-Pedersen C; Gislason G; Olesen JB
Thromb Haemost; 2017 Jun; 117(6):1182-1191. PubMed ID: 28300865
[TBL] [Abstract][Full Text] [Related]
33. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
35. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
[TBL] [Abstract][Full Text] [Related]
36. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies.
Wu O; Morris S; Larsen TB; Skjøth F; Evans A; Bowrin K; Wojciechowski P; Margas W; Huelsebeck M
Cardiovasc Ther; 2022; 2022():2756682. PubMed ID: 35801133
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
39. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.
Palareti G; Antonucci E; Legnani C; Mastroiacovo D; Poli D; Prandoni P; Tosetto A; Pengo V; Testa S; Ageno W;
BMJ Open; 2020 Nov; 10(11):e040449. PubMed ID: 33247017
[TBL] [Abstract][Full Text] [Related]
40. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]